A

Axiom Bio

AI-driven hepatotoxicity prediction for drugs

Scientist – Cell Biology

Translational Research & Bench BiologyConfirmed live in the last 24 hours
Full-timeSouth San Francisco, CA, USANo salary listedIn-person

About the Job

Requirements

  • Deep understanding of cell biology and human physiology.
  • Ability to invent and refine biological models and assays to answer questions that established protocols cannot address.
  • Commitment to reproducibility, biological relevance, and data quality, with attention to detail to identify subtle sources of error.
  • Ability to design decisive experiments with strong controls and draw evidence-supported conclusions to rigorous scientific standards.
  • Ability to interpret complex biological phenotypes and distinguish meaningful effects from noise, confounding factors, and experimental artifacts.
  • Curiosity about cell biology, experimental technologies, and drug discovery, and willingness to master new methods.
  • Ability to communicate complex science clearly and make a compelling case for scientific ideas.
  • Experience with primary human cell culture, induced pluripotent stem cell culture and differentiation, and cell engineering.
  • Experience developing physiologically relevant models, including co-cultures, organoids, spheroids, and engineered tissues.
  • A strong foundation in cell biology, molecular biology, physiology, and pharmacology.
  • Expertise in high-content imaging, Cell Painting, fluorescence microscopy, live-cell imaging, and image-based phenotypic screening.
  • Experience developing, miniaturizing, and automating assays for high-throughput screening.
  • Experience measuring cell viability, mitochondrial function, oxidative stress, endoplasmic reticulum stress, apoptosis, inflammation, and other functional responses.
  • Familiarity with RNA sequencing, proteomics, metabolomics, and methods that combine multiple biological measurements.
  • Strong experimental design and quantitative analysis skills, including dose-response analysis, statistical methods, assay validation, and quality control.

Responsibilities

  • Build human cell models that accurately predict drug-induced toxicity in the liver, kidney, heart, and immune system, as well as pharmacokinetic properties such as exposure and metabolism.
  • Design and optimize physiologically relevant systems using primary human cells, multicellular cultures, organoids, and other advanced models.
  • Develop high-content assays that reveal how drugs disrupt cellular function and cause injury.
  • Combine live-cell imaging, transcriptomics, proteomics, and mass spectrometry to connect changes in cell behavior with underlying molecular mechanisms.
  • Work with robotics engineers to build a generalizable robotics platform for assay development and turn complex assays into reproducible, high-throughput experimental workflows.
  • Establish rigorous validation and quality control standards to ensure consistent results across cell batches, plates, operators, and laboratories.
  • Investigate mechanisms of drug-induced injury and design experiments that distinguish meaningful biological effects from measurement artifacts.
  • Partner with computational scientists and drug discovery teams to generate large-scale biological datasets with the quality and depth needed to predict toxicity and guide drug development.
  • Partner with pharmaceutical companies and AI labs to interpret Axiom’s data, uncover biochemical mechanisms behind observed effects, and guide drug discovery decisions.

About the Company

Axiom Bio

AI-driven hepatotoxicity prediction for drugs

Axiom Bio provides an AI-driven platform for predictive toxicology that helps drug researchers identify potential liver toxicity early in development. The platform uses a large proprietary dataset—over 115,000 small molecules screened on primary human liver cells with imaging and biochemical readouts, plus PK and clinical data—to predict drug-induced liver injury and related toxicity pathways from a molecule’s structure. It differentiates itself through its large human-toxicity dataset and by offering mechanistic insights (such as mitochondrial toxicity, ER stress, and ROS) at a low per-molecule cost. The goal is to speed up safe drug development by de-risking preclinical pipelines and reducing reliance on animal testing.

Company size
11-50
Company stage
Seed
Total funding
$15M
Headquarters
San Francisco, CA
Founded
2024

Recently Posted Jobs

Explore more opportunities at Axiom Bio

See more jobs